Medigene AG Total Liabilities
Medigene AG total liabilities. Based on the latest financial reports, Medigene AG (MDG1) has total liabilities worth €9.15 Million EUR (≈ $10.70 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Medigene AG liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Medigene AG (2006–2023)
Total liabilities of Medigene AG from 2006 to 2023. This chart illustrates how Medigene AG's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Medigene AG to see how much of total assets are deployed in long-term investments.
Medigene AG Competitors by Total Liabilities
The table below lists competitors of Medigene AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Diadrom Holding AB
ST:DIAH
|
Sweden | Skr10.12 Million |
|
NOVRA TECHNOLOGIES INC.
F:7CV
|
Germany | €9.35 Million |
|
CAP-EX IRON ORE
F:X0V
|
Germany | €146.95K |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
USA | $1.18 Million |
|
Kestrel Gold Inc
V:KGC
|
Canada | CA$63.05K |
|
Argent Biopharma Ltd
AU:RGT
|
Australia | AU$11.10 Million |
Liability Composition Analysis (2006–2023)
This chart breaks down Medigene AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MDG1 current and non-current assets.
Liquidity & Leverage Metrics
Medigene AG Total Liabilities Ratios Explained
Medigene AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medigene AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medigene AG (2006–2023)
The table below shows the annual total liabilities of Medigene AG from 2006 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €10.65 Million ≈ $12.45 Million |
-27.31% |
| 2022-12-31 | €14.65 Million ≈ $17.13 Million |
-0.02% |
| 2021-12-31 | €14.65 Million ≈ $17.13 Million |
-32.15% |
| 2020-12-31 | €21.60 Million ≈ $25.25 Million |
-21.16% |
| 2019-12-31 | €27.39 Million ≈ $32.02 Million |
+23.58% |
| 2018-12-31 | €22.16 Million ≈ $25.91 Million |
-13.99% |
| 2017-12-31 | €25.77 Million ≈ $30.13 Million |
-22.20% |
| 2016-12-31 | €33.12 Million ≈ $38.72 Million |
+40.69% |
| 2015-12-31 | €23.54 Million ≈ $27.52 Million |
+5.99% |
| 2014-12-31 | €22.21 Million ≈ $25.97 Million |
+35.61% |
| 2013-12-31 | €16.38 Million ≈ $19.15 Million |
-3.88% |
| 2012-12-31 | €17.04 Million ≈ $19.92 Million |
+217.91% |
| 2011-12-31 | €5.36 Million ≈ $6.27 Million |
-69.20% |
| 2010-12-31 | €17.40 Million ≈ $20.35 Million |
+25.65% |
| 2009-12-31 | €13.85 Million ≈ $16.19 Million |
-12.56% |
| 2008-12-31 | €15.84 Million ≈ $18.52 Million |
+33.83% |
| 2007-12-31 | €11.84 Million ≈ $13.84 Million |
-24.24% |
| 2006-12-31 | €15.62 Million ≈ $18.27 Million |
-- |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more